Nanotechnology in the treatment of inflammatory bowel diseases
- 1 September 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (9) , 903-918
Abstract
Treatment of inflammatory bowel diseases (IBD) is only aimed to block or inhibit the pathogenetic steps of the inflammatory cascade. Side effects of systemic therapies, poor targeting of orally administered topical drug and low adherence to prescription represent frequent therapeutic challenges. Recent observations suggest that nanotechnology could provide amazing advantage in this field since particles having dimension in the nanometer scale (nanoparticles) can modify pharmacokinetic step of biologic and conventional therapeutic agents with a better delivery of drugs within the intestinal inflammatory cells. The aim of this review was to provide the clinician with an insight into the potential role of nanotechnology in the treatment of IBD. A systematic search (PubMed) for experimental studies on the treatment of intestinal inflammation using nanotechnology for the delivery of drugs. The size of the pharmaceutical formulation is inversely related to specificity for inflammation. Nanoparticles can penetrate epithelial and inflammatory cells resulting in much higher, effective and long-acting concentrations than can be obtained using conventional delivery systems. From a practical point of view, this should lead to improvements in both efficacy and adherence to treatment, providing patients with the prospect of stable and prolonged remissions with reduced drug loadings. Reduced systemic side effects could also be expected.Keywords
This publication has 103 references indexed in Scilit:
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current managementJournal of Crohn's and Colitis, 2012
- Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitisCochrane Database of Systematic Reviews, 2012
- Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis2012
- Adverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database of Systematic Reviews, 2011
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?American Journal of Gastroenterology, 2011
- Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's diseaseCochrane Database of Systematic Reviews, 2011
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current managementJournal of Crohn's and Colitis, 2010
- Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitisCochrane Database of Systematic Reviews, 2010
- The long journey of salicylates in ulcerative colitis: The past and the futureJournal of Crohn's and Colitis, 2009
- Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.Gut, 1992